ESR1 and breast carcinoma: Because SLFN11 determines response to a wide range of DNA damaging drugs in addition to PARPIs, further clinical studies and assays are warranted to score SLFN11 expression in tumor samples like estrogen receptor is examined routinely by immunohistochemistry in breast cancer.